NEWS & INSIGHTS

DUBLIN, IRELAND – May 15, 2018 – ATXA Therapeutics Limited, an Irish company developing novel therapeutic drugs for the treatment of Pulmonary Arterial Hypertension (PAH) and for other related cardiovascular conditions, has secured €2.5 million funding under the Europe...

DUBLIN, IRELAND – April 3, 2018 – ATXA Therapeutics Limited Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will be attending the 2018 Medtech Strategist Innovation Summit in Dublin, Ireland, from April 17-19, 2018. The event will take place at...

DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), is pleased to announce that the United States Food...

DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that the European Medicines Age...

DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that its Founder and Chief Scien...